Close Menu

proteomic-based diagnostics

The companies will evaluate the performance of Proteomics International's PromarkerD test for predicting decline in kidney function and drug response.

Founded last year, the company plans to develop mass spec-based tests to protein isoforms using a workflow that eliminates both LC and protein digestion.

Genome Canada and its partners recently funded two new initiatives with C$255 that will back precision medicine, genomics, and technology development.

The company is developing an epilepsy test based on inflammatory proteins in patient blood that is intended for ruling out patients with seizure-like symptoms.

The company presented new data at a meeting last week showing that Vectra DA predicted whether patients would do better on one or the other of two possible second-line therapies.

NEW YORK (GenomeWeb) – Biocartis announced today that it has raised €64.5 million ($84 million) in a round of private financing.

NEW YORK (GenomeWeb) – Newomics said today that it has received from the National Institutes of Health two Small Business Innovation Research Phase I grants totaling $908,000.

NEW YORK (GenomeWeb) – Integrated Diagnostics said this week that it has obtained $47.25 million in funding, $30.25 million from the closing of its Series B round and $17 million in non-dilutive debt financing from Life Sciences Alternative Funding.

NEW YORK (GenomeWeb News) – Biodesix today said that it has closed an $8.3 million Series E round of private financing.

The story has been updated to include comments from Vermillion's conference call on Thursday.

Pages

Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.

Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.

Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.

In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.